ARA-290

ARA-290 is an 11-amino-acid peptide modeled from a region of erythropoietin but engineered to separate EPO’s tissue-protective signaling from its blood-cell-producing effects. Its primary research target is the innate repair receptor, or IRR, a heteromeric receptor complex formed from the erythropoietin receptor and the β-common receptor CD131. Activation of this receptor has been associated with anti-inflammatory signaling, cytoprotection, and tissue-repair pathways.

This distinction is important because conventional erythropoietin can increase red-blood-cell production, which limits its usefulness in many tissue-protection applications. ARA-290 was developed specifically to retain signaling associated with repair while avoiding significant erythropoietic activity. In experimental models, IRR activation has been studied in relation to inflammatory cytokines, peripheral nerve injury, neuropathic pain, and recovery following tissue damage.

ARA-290 has also progressed beyond purely preclinical research. Human studies in sarcoidosis-associated and diabetes-associated small-fiber neuropathy have reported improvements in neuropathic symptom measures, and some studies observed increases in corneal nerve-fiber density. These findings make ARA-290 unusual among research peptides because it has both mechanistic laboratory evidence and controlled human clinical data.